Gillum Matthew P, Potthoff Matthew J
Section for Liver Metabolism and Metabolic Imaging, the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark Department of Biomedical Sciences, the Novo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, 2200 Copenhagen, Denmark
Department of Pharmacology, University of Iowa Carver College of Medicine, Iowa City, IA 52242, U.S.A. Fraternal Order of Eagles Diabetes Research Center, University of Iowa Carver College of Medicine, Iowa City, IA 52242, U.S.A.
Biochem J. 2016 May 1;473(9):1125-7. doi: 10.1042/BCJ20160004.
Fibroblast growth factor 21 (FGF21) is an endocrine hormone that regulates carbohydrate and lipid metabolism. In humans, circulating FGF21 is inactivated by proteolytic cleavage of its C-terminus, thereby preventing signalling through a receptor complex. The mechanism for this cleavage event and the factors contributing to the post-translational regulation of FGF21 activity has previously been unknown. In a recent issue of the Biochemical Journal, Zhen et al. have identified fibroblast activation protein (FAP) as the endopeptidase responsible for this site-specific cleavage of human FGF21 (hFGF21), and propose that inhibition of FAP may be a therapeutic strategy to increase endogenous levels of active FGF21.
成纤维细胞生长因子21(FGF21)是一种调节碳水化合物和脂质代谢的内分泌激素。在人类中,循环中的FGF21通过其C末端的蛋白水解切割而失活,从而阻止通过受体复合物进行信号传导。此前,这种切割事件的机制以及促成FGF21活性翻译后调控的因素一直未知。在最近一期的《生物化学杂志》上,甄等人确定了成纤维细胞激活蛋白(FAP)是负责对人FGF21(hFGF21)进行这种位点特异性切割的内肽酶,并提出抑制FAP可能是一种提高内源性活性FGF21水平的治疗策略。